Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer.

IF 3.2 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
International Journal of Medical Sciences Pub Date : 2025-06-12 eCollection Date: 2025-01-01 DOI:10.7150/ijms.113736
Guo-Bin Song, Lin Xiang, Tian Peng, Ya-Nan Li, Hou-Qun Ying, Xue-Xin Cheng
{"title":"Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer.","authors":"Guo-Bin Song, Lin Xiang, Tian Peng, Ya-Nan Li, Hou-Qun Ying, Xue-Xin Cheng","doi":"10.7150/ijms.113736","DOIUrl":null,"url":null,"abstract":"<p><p>ACTL6A, a core subunit of the SWI/SNF chromatin remodeling complex, has emerged as a critical oncogenic driver across multiple malignancies. Recent studies reveal that aberrant ACTL6A overexpression promotes tumor initiation, progression, and metastasis by orchestrating chromatin remodeling, transcriptional reprogramming, and crosstalk with key signaling pathways (e.g., Hippo/YAP, Notch, and PI3K/AKT). This review systematically synthesizes evidence from <i>in vitro</i>, <i>in vivo</i>, and clinical studies spanning hepatocellular carcinoma, breast cancer, glioblastoma, and 10 other cancer types, highlighting ACTL6A's dual role as a chromatin remodeler and an independent oncogenic effector. Key mechanisms include sustaining cancer stemness, suppressing apoptosis, enhancing DNA repair, and driving metabolic reprogramming. Clinically, ACTL6A overexpression correlates with advanced tumor stage, therapy resistance, and poor prognosis, positioning it as a promising prognostic biomarker and therapeutic target. We further discuss emerging strategies to inhibit ACTL6A (e.g., siRNA, small-molecule inhibitors) and propose combinatorial approaches to overcome drug resistance. By integrating multi-omics data and preclinical models, this review not only clarifies ACTL6A's context-dependent oncogenic networks but also bridges mechanistic insights to translational challenges, offering a roadmap for future research and therapeutic development.</p>","PeriodicalId":14031,"journal":{"name":"International Journal of Medical Sciences","volume":"22 12","pages":"2906-2918"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243864/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/ijms.113736","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

ACTL6A, a core subunit of the SWI/SNF chromatin remodeling complex, has emerged as a critical oncogenic driver across multiple malignancies. Recent studies reveal that aberrant ACTL6A overexpression promotes tumor initiation, progression, and metastasis by orchestrating chromatin remodeling, transcriptional reprogramming, and crosstalk with key signaling pathways (e.g., Hippo/YAP, Notch, and PI3K/AKT). This review systematically synthesizes evidence from in vitro, in vivo, and clinical studies spanning hepatocellular carcinoma, breast cancer, glioblastoma, and 10 other cancer types, highlighting ACTL6A's dual role as a chromatin remodeler and an independent oncogenic effector. Key mechanisms include sustaining cancer stemness, suppressing apoptosis, enhancing DNA repair, and driving metabolic reprogramming. Clinically, ACTL6A overexpression correlates with advanced tumor stage, therapy resistance, and poor prognosis, positioning it as a promising prognostic biomarker and therapeutic target. We further discuss emerging strategies to inhibit ACTL6A (e.g., siRNA, small-molecule inhibitors) and propose combinatorial approaches to overcome drug resistance. By integrating multi-omics data and preclinical models, this review not only clarifies ACTL6A's context-dependent oncogenic networks but also bridges mechanistic insights to translational challenges, offering a roadmap for future research and therapeutic development.

肌动蛋白样蛋白6A作为肿瘤基因和治疗靶点。
ACTL6A是SWI/SNF染色质重塑复合体的核心亚基,已成为多种恶性肿瘤的关键致癌驱动因素。最近的研究表明,异常的ACTL6A过表达通过协调染色质重塑、转录重编程和与关键信号通路(如Hippo/YAP、Notch和PI3K/AKT)的串扰,促进肿瘤的发生、进展和转移。本综述系统地综合了来自肝细胞癌、乳腺癌、胶质母细胞瘤和其他10种癌症类型的体外、体内和临床研究的证据,强调了ACTL6A作为染色质重塑剂和独立致癌效应剂的双重作用。关键机制包括维持癌症干细胞、抑制细胞凋亡、增强DNA修复和驱动代谢重编程。临床上,ACTL6A过表达与肿瘤分期、治疗耐药、预后不良相关,是一种有前景的预后生物标志物和治疗靶点。我们进一步讨论了抑制ACTL6A的新策略(例如siRNA,小分子抑制剂),并提出了克服耐药性的组合方法。通过整合多组学数据和临床前模型,本综述不仅阐明了ACTL6A的环境依赖性致癌网络,还将机制见解与转化挑战联系起来,为未来的研究和治疗开发提供了路线图。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Medical Sciences
International Journal of Medical Sciences MEDICINE, GENERAL & INTERNAL-
CiteScore
7.20
自引率
0.00%
发文量
185
审稿时长
2.7 months
期刊介绍: Original research papers, reviews, and short research communications in any medical related area can be submitted to the Journal on the understanding that the work has not been published previously in whole or part and is not under consideration for publication elsewhere. Manuscripts in basic science and clinical medicine are both considered. There is no restriction on the length of research papers and reviews, although authors are encouraged to be concise. Short research communication is limited to be under 2500 words.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信